RSV mRNA LNP CL-0137 / Sanofi - LARVOL DELTA

Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older (clinicaltrials.gov) - P1/2 | N=790 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Apr 2025

Enrollment open • Lipid Nanoparticle • Trial completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections

Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older (clinicaltrials.gov) - P1/2 | N=790 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Apr 2025 ➔ Apr 2026

Trial completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older (clinicaltrials.gov) - P1/2 | N=790 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older (clinicaltrials.gov) - P1/2 | N=790 | Recruiting | Sponsor: Sanofi

New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections